secwatch.observer — SEC 8-K summary
======================================

Issuer:     AMGEN INC (AMGN)
CIK:        0000318154
Form:       8-K
Filed at:   2022-10-20T23:59:59+00:00
Accession:  0001193125-22-265755
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amgen completes $3.7B acquisition of ChemoCentryx, adding TAVNEOS to portfolio
------------------------------------------------------------------------------

- Acquisition closed at $52 per share in cash, aggregate consideration ~$3.7 billion.
- Adds TAVNEOS (avacopan), a first-in-class oral therapy for severe active ANCA-associated vasculitis.
- Also includes three early-stage drug candidates targeting chemoattractant receptors and an oral checkpoint for cancer.
- TAVNEOS approved by FDA in Oct 2021; being studied in hidradenitis suppurativa and C3 glomerulopathy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/318154/000119312522265755/0001193125-22-265755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/318154/000119312522265755/d414605d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-265755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer